Vimta Labs Ltd-$ press release, Q2 FY27
Vimta says revenue from its biologics CRAD services has started, which it calls a significant milestone.
By ScoutQuest · · 1 min read
- Basic EPS, Q2 FY27
- ₹4.6 (up 3.4% YoY)
- EBITDA margin, Q2 FY27
- 35.5% (reported earlier) from 36.4% in Q1 FY27
- Biologics CRAD services revenue
- revenue from its biologics CRAD services has started, which it calls a significant milestone
- Release
- Results press release
- Period
- Q2 FY27
_Basis not stated · Q2 & H1 FY27_
📈 Basic EPS, Q2 FY27: ₹4.6 (up 3.4% YoY)
📉 EBITDA margin, Q2 FY27: fell to 35.5% (reported earlier) from 36.4% in Q1 FY27
📊 The company's managing director says the start of revenue from Vimta's biologics CRAD services is a significant milestone that broadens its scientific capabilities.
📉 EBITDA margin slipped to 35.5% (reported earlier) in Q2 FY27 from 36.4% in Q1 FY27, though it was above the 35.3% of Q2 FY26.
Also from Vimta Labs
Vimta Labs Q2 FY27 total income up 9.9% YoY to ₹1,149 Mn, PAT up 3.5%
30 Oct 2026
Q2 FY27 results with unmodified limited review; US wholly owned subsidiary noted
30 Oct 2026
Vimta Labs schedules analyst/investor conference call for 30 October 2026 at 2:30 PM IST post Q2 FY27 results
26 Oct 2026
More numbers
- Total income, Q2 FY27₹1,149 Mn
- PBT, Q2 FY27₹275 Mn
- PAT, Q2 FY27₹206 Mn
- Basic EPS, Q2 FY27₹4.6
- Total income, H1 FY27Rs. 2,278 Mn
- PBT, H1 FY27Rs. 559 Mn
- EBITDA margin, Q2 FY2735.5%
- PAT margin, Q2 FY2717.9%
- EBITDA margin, H1 FY2736.0%
- PAT margin, H1 FY2718.3%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.